The Avastin vs Visudyne for Neovascular AMD Study

Sponsor
St. Erik Eye Hospital
Study ID
NCT00390026
Phase
PHASE3
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The object of the study is to compare the treatment effect of bevacizumab (Avastin), an antibody targeting vascular endothelial growth factor, with verteporfin photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration, the leading cause of vision severe loss in the Western world.

Key Dates

Start date
Nov 30, 2006
Status verified
Jan 2024
Primary completion
Nov 30, 2008
Completion
Nov 30, 2008

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Avastin
  • Active Comparator: Visudyne

Primary Outcome Measure

Proportion of patients losing less than 15 letters on the ETDRS visual acuity chart. [ Time Frame: 1 year ]

Related Studies